Engineered immune cells have shown great promise for treating certain types of chemotherapy resistant and refractory cancers. The success of this approach depends on optimal and selective engineering of immune cells followed by extensive ex-vivo characterization to identify the right CAR or TCR construct that can maintain immune cell activation, proliferation, potency and persistence.

What Agilent is to offer?

Agilent offers a growing number of solutions for cell engineering, immunophenotyping, and high-throughput screening of optimal engineered immune cells in the context of the tumor microenvironment models. Assess engineered immune cell potency, exhaustion, and metabolic phenotypes to determine cell fate, fitness and function with these next generation solutions.